Results from the first randomised trial evaluating microRNA inhibition to treat heart failure were presented today. The trial investigated CDR132L, an oligonucleotide-based inhibitor directed against ...

Please provide your email address to receive an email when new articles are posted on . An agent designed to inhibit microRNA that drives adverse cardiac remodeling did not benefit patients with ...

Ankylosing spondylitis (AS) is increasingly recognized as an independent risk factor for premature myocardial infarction (MI), yet the molecular bridge linking chronic axial inflammation to acute ...

Ankylosing spondylitis (AS) is increasingly recognized as an independent risk factor for premature myocardial infarction (MI), yet the molecular bridge linking chronic axial inflammation to acute ...

The role of long-term beta-blocker therapy after a myocardial infarction in patients without left ventricular systolic dysfunction or heart failure is unclear in the era of contemporary ...